Trabektedyna w leczeniu raka jajnika

• Authors: Janina Markowska , Mariusz Bidziński , Zbigniew Kojs , Jan Kotarski

Title variants

EN

Trabectedin for the treatment of ovarian cancer

• Languages of publication: PL EN

Abstracts

PL

W pracy opisano postępowanie terapeutyczne standardowo stosowane u chorych na raka jajnika, oparte m.in. na rekomendacjach Polskiego Towarzystwa Ginekologii Onkologicznej. Terapia obejmuje postępowanie operacyjne i systemowe leczenie cytostatykami (standardowo: pochodnymi platyny i paklitakselu w pierwszej linii leczenia). Istotnym elementem leczenia operacyjnego jest całkowita, ewentualnie optymalna cytoredukcja. Również odpowiedź na pierwszą linię adiuwantowej chemioterapii stanowi ważny czynnik prognostyczny. Podawanie bewacyzumabu w pierwszej linii leczenia chemicznego i w platynowrażliwym nawrotowym raku jajnika jest skutecznym sposobem terapii. U pacjentek ze wznową (w czasie 6–12 miesięcy po pierwszej linii chemioterapii) raka jajnika – częściowo platynowrażliwego – skutecznym lekiem okazała się trabektedyna (Yondelis). Stosowana z pegylowaną liposomalną doksorubicyną, wydłużyła znamiennie czas wolny od progresji (9,2 vs 7,2 miesięca, p = 0,017) w stosunku do stosowanej wyłącznie liposomalnej doksorubicyny. Wykazano też wydłużenie całkowitego przeżycia (22,4 vs 18,9 miesiąca, p = 0,835), choć statystycznie różnica nie była znamienna. Zaletami trabektedyny stosowanej we wznowie raka jajnika są zwiększenie wrażliwości guza na preparaty platyny oraz niska toksyczność.

EN

The paper describes standard therapeutic management used in patients with ovarian cancer, which is based, among other things, on the recommendations of the Polish Gynecological Oncology Society. Therapeutic management encompasses surgical treatment and systemic therapy with cytostatic drugs (typically derivatives of platinum and paclitaxel as first-line therapy). Total or optimal cytoreduction is an important element of surgical treatment. Additionally, the response to first-line adjuvant chemotherapy is a highly significant prognostic factor. Bevacizumab is an effective treatment in the first-line chemotherapy and in patients with platinum-sensitive relapsed ovarian cancer. Trabectedin (Yondelis) used in patients with relapsed ovarian cancer (partially platinum-sensitive) (relapse within 6–12 months after first-line chemotherapy) proved to be an effective drug. Used in combination with pegylated liposomal doxorubicin, the drug significantly improved progressionfree survival (time to progression ranging between 9.2 vs. 7.2 months, p = 0.017) as compared to pegylated liposomal doxorubicin alone. Improvement of overall survival was also demonstrated (22.4 vs. 18.9 months, p = 0.835), however, it was insignificant. In addition, trabectedin used in relapsed ovarian cancer increased sensitivity to platinum and exhibited low toxicity.

Keywords

EN

chemioterapia; operacje raka jajnika; rak jajnika; trabektedyna

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2017
• Volume: 15
• Issue: 3
• Pages: 218–223

Contributors

author

Janina Markowska

• Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Polska

author

Mariusz Bidziński

• Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warszawa, Polska

author

Zbigniew Kojs

• Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Krakowie, Kraków, Polska

author

Jan Kotarski

• I Katedra i Klinika Ginekologii Onkologicznej i Ginekologii, Uniwersytet Medyczny w Lublinie, Lublin, Polska

References

• 1. Wojciechowska U, Didkowska J, Zatoński W: Nowotwory zło- śliwe w Polsce w 2012 roku. Krajowy Rejestr Nowotworów, Warszawa 2014.
• 2. Survival Rates for Ovarian Cancer, by Stage. Available from: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html.
• 3. Basta A, Bidziński M, Bieńkiewicz A et al.: Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. Curr Gynecol Oncol 2017: 15: 5–23.
• 4. Wallace S, Kumar A, Mc Gree M et al.: Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol 2017; 145: 21–26.
• 5. Raspagliesi F, Bogani G, Ditto A et al.: Implementation of extensive cytoreduction resulted in improved survival outcomes for patients with newly diagnosed advanced-stage ovarian, tubal, and peritoneal cancers. Ann Surg Oncol 2017; 24: 3396–3405.
• 6. Elattar A, Bryant A, Winter-Roach BA et al.: Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011; (8): CD007565.
• 7. Shih KK, Chi DS: Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 2010; 21: 75–80.
• 8. Ozols RF, Bundy BN, Greer BE et al.; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194–3200.
• 9. Eskander RN, Tewari KS: American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer. Int J Gynecol Cancer 2014; 24: 13–18.
• 10. Wright AA, Cronin A, Milne DE et al.: Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 2015; 33: 2841–2847.
• 11. Ledermann JA, Raja FA, Fotopoulou C et al.; ESMO Guidelines Working Group: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi24–vi32.
• 12. Chen J, Wang J, Zhang Y et al.: Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture. J Biosci Bioeng 2014; 118: 214–222.
• 13. Craveiro V, Yang-Hartwich Y, Holmberg JC et al.: Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013; 2: 751–762.
• 14. Friedlander M, Trimble E, Tinker A et al.; Gynecologic Cancer InterGroup: Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771–775.
• 15. du Bois A, Reuss A, Pujade-Lauraine E et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115: 1234–1244.
• 16. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al.: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323–3329.
• 17. Coleman RL, Brady MF, Herzog TJ et al.: Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 779–791.
• 18. Bilgetekin I, Cetin B, Ozet A: Antiangiogenic therapy in ovarian cancer – for whom and when? Curr Gynecol Oncol 2017; 15: 78–85.
• 19. Kaye SB, Colombo N, Monk BJ et al.: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays thirdline chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011; 22: 49–58.
• 20. Monk BJ, Herzog TJ, Kaye SB et al.: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107–3114.
• 21. Azvolinsky A: ESGO: Role for Trabectedin Plus Pegylated Doxorubicin in Advanced Ovarian Cancer, OVA-301 Final Results Presented at ESGO – September 16, 2011. Available from: http:// www.cancernetwork.com/ovarian-cancer/esgo-role-trabectedinplus-pegylated-doxorubicin-advanced-ovarian-cancer-ova301-final-results.
• 22. Krasner CN, Poveda A, Herzog T et al.: Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. 45th Annual Meeting of the American Society of Clinical Oncology, abstr. 5526.
• 23. Sliesoraitis S, Chikhale PJ: Carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15: 13–18.
• 24. Adam JP, Boumedien F, Letarte N et al.: Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2017; 147: 47–53.
• 25. Poveda A, Vergote I, Tjulandin S et al.: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22: 39–48.
• 26. Fisher M, Gore M: Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial. Value Health 2013; 16: 507–516.
• 27. Di Napoli M, Della Pepa C, Arenare L et al.: Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. Support Care Cancer 2017; 25: 1743–1748.
• 28. Monk BJ, Lorusso D, Italiano A et al.: Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treat Rev 2016; 50: 175–182.
• 29. Lorusso D, Perotto S: Ovarian cancer treatment in mutation carriers/BRCAness. Minerva Ginecol 2016; 68: 566–578.

• Document Type: article